Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused ...

Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an Inv ...

Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...

The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...

U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...

In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...